On the heels of a positive recommendation by EU Reviewers drug, the US Food and Drug Administration this week approved a novel viral drug therapy for cancer, Known chemically as talimogene laherparepvec, or T-Vec. Developed by pharmaceutical company Amgen, T-Vec use a genetically engineered virus to target and destroy cancer cells. The drug itself not only kills cancer cells, but Also Stimulates the immune system to aid in the fight. Amgen will market the cancer treatment under the brand name Imlygic. Imlygic is an oncolytic (cancer-killing) drug use That the cold sore-causing herpes viruses as STI base. The virus was genetically engineered to attack the cancer cells Rapidly-dividing while ignoring the slow-growing healthy cells. Once the drug to cell Enters, It Takes over the host’s DNA replication system and to make copies of Begins itself. These multiple copies Quickly, Causing the cancer cell to burst. Amgen Also removed a gene from the virus evades That Allows it to detection by the host. The now very visible virus will Stimulate an immune response when it attacking cancer cells Begins, Causing them to explode. Researchers Also added a gene for the production of the GM-CSF protein, Which is another immune system stimulant. As a result of esta combination, the immune system goes into overdrive, joining the Imlygic in mounting an attack Effectively Against Causing the cancer cells. Related: The first FDA-approved 3D-printed drug dissolves in water almost Instantly
UNLIKE That requires oral chemotherapy treatments DOSAGES, doctors inject the drug Imlygic Directly into the tumor, destroying the cells in a targeted attack. Clinical trials Imlygic Showed That was reliable to shrink a tumor significantly more than Control WHO Patients only received the GM-CSF protein therapy. Imlygic shows promise, but it May not be a cure-all – even though it reduced the size of the tumor in trials, patient mortality was not reduced With the drug. Imlygic is only now being used to treat melanoma -a deadly form of skin Cancer- and other solid tumor cancers. “T-Vec Represents an Important Milestone in using viruses as the vehicle to Stimulate immune response and fight cancer,” Said Tim Turnham, executive director of the Melanoma Research Foundation. Amgen will begin offering Imlygic to Patients in the coming weeks With an average cost of $ 65. 000. The company is Continuing to study Also the treatment in combination with other vouchers Immunotherapies to see if it can improve increase cancer survival rates.